transcatheter aortic valve implantation Archives

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Management of patients with cardiac amyloidosis and concomitant high-grade aortic stenosis is challenging. This article reports the case of a 79-year-old man with transcatheter aortic valve implantation (TAVI) complicated by low cardiac output during release of a Medtronic Evolut R 34 mm valve. After initiation of mechanical circulatory support, the TAVI valve was successfully implanted despite ongoing ventricular fibrillation. The ventricular fibrillation was successfully treated with injection of potassium into the aorta, with subsequent defibrillation and ventricular pacing. Moreover, pharmacological management of transient severe LV dysfunction and high-grade mitral regurgitation finally led to a favourable course.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0078

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Peter Ong, Stephan Hill and Dominik Bierbaum et al. Successful TAVI Despite Sudden Low Output and Ventricular Fibrillation in a Patient with Cardiac Amyloidosis. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0078

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Transcatheter aortic valve replacement (TAVR) is currently a widely used option for patients with severe symptomatic aortic stenosis with high to low surgical risk. However, aortic regurgitation (AR) remains an “off-label” indication for TAVR, particularly for patients with mild or absent leaflet calcification or aortic annulus dimensions beyond the size of the bioprosthesis, which increase the risk of dislocation. With advances in transcatheter heart valve devices, the safety and efficacy of TAVR in treating patients with severe pure native AR has gained acceptance.

This article examines current evidence and clinical practice, and presents technological advancements in devices for AR.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0033

Ran Liu, Zhaolin Fu and Jing Yao et al. Transcatheter Aortic Valve Replacement for Aortic Regurgitation – A Review. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0033

CVIA Journal

Tag: transcatheter aortic valve implantation

Successful TAVI Despite Sudden Low Output and Ventricular Fibrillation in a Patient with Cardiac Amyloidosis

Transcatheter Aortic Valve Replacement for Aortic Regurgitation